Defunct Company
Total Trials
21
As Lead Sponsor
As Collaborator
0
Total Enrollment
2,229
NCT00038428
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 30, 2001
Completion: Jul 31, 2005
NCT00035841
Phase 2 Study of TLK286 in Metastatic Breast Cancer
Start: Apr 30, 2002
Completion: Jul 31, 2004
NCT00035867
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
Phase: Phase 1/2
Completion: May 31, 2007
NCT00040638
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
Start: Jul 31, 2002
Completion: Aug 31, 2003
NCT00047801
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
Start: Oct 31, 2002
Completion: Sep 30, 2004
NCT00051948
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Start: Jan 31, 2003
Completion: Jan 31, 2005
NCT00052065
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Start: Feb 28, 2003
Completion: Mar 31, 2006
NCT00057720
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Phase: Phase 3
Start: Jun 30, 2003
Completion: Dec 31, 2006
NCT00077883
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Start: Feb 29, 2004
Completion: Mar 31, 2007
NCT00088556
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Start: Aug 31, 2004
Completion: May 31, 2009
NCT00102973
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Start: Dec 31, 2004
Completion: Jul 31, 2008
NCT00280631
Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
Start: Feb 28, 2006
Completion: Jun 30, 2008
NCT00350948
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Start: May 31, 2006
Completion: Dec 31, 2008
NCT00700206
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Start: May 31, 2008
Completion: Jul 31, 2011
NCT00701870
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
Start: Oct 31, 2008
Completion: Nov 30, 2008
NCT00909584
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia
Start: Apr 30, 2009
Completion: May 31, 2013
NCT01062152
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase: Phase 1
Start: Nov 30, 2009
Completion: Mar 31, 2013
NCT01148108
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Start: Jun 30, 2010
Completion: Sep 30, 2012
NCT01422486
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Start: Oct 31, 2011
Completion: Feb 28, 2013
NCT01459159
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome